ClinConnect ClinConnect Logo
Search / Trial NCT06387394

A Study to Assess BOTOX Injections in Adult Participants for the Change of Masseter Muscle Prominence

Launched by ABBVIE · Apr 24, 2024

Trial Information

Current as of May 24, 2025

Active, not recruiting

Keywords

Botox Onabotulinumtoxin A Masseter Muscle Prominence

ClinConnect Summary

This clinical trial is studying the use of BOTOX injections to help reduce the appearance of a prominent masseter muscle, which is the muscle in your jaw used for chewing. Some people feel that having a wider jawline is not aesthetically pleasing, and this study aims to see how safe and effective BOTOX is for adults with this condition. If you are an adult aged between 18 and 65 with a significant prominence in both sides of your jaw, you might be eligible to participate.

During the trial, participants will be divided into two groups: one will receive BOTOX injections, while the other will receive a placebo (a substance with no active treatment). This means there's a chance you could receive the placebo. You will receive injections in both sides of your jaw and may have the option to receive more BOTOX after the initial treatment. Throughout the study, you will attend regular visits to monitor your progress and any side effects. It’s important to note that participation may require more time and visits than standard treatment, as the study aims to thoroughly assess how well the treatment works and how safe it is.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • * Participant meets the following criteria:
  • Bilateral Grade 4 or Grade 5 Masseter Muscle Prominence (MMP) (identical grades for left and right sides of the face), as determined at by the investigator using the Masseter Muscle Prominence Scale (MMPS).
  • Bilateral Grade 4 or Grade 5 MMP (identical grades for left and right sides of the face), as determined by the participant using the Masseter Muscle Prominence Scale - Participant (MMPS-P).
  • Investigator and participant scoring of MMPS and MMPS-P must be the same.
  • Body mass index (BMI) ≤ 30 kg/m\^2 using the calculation: BMI = weight (kg)/height (m)\^2.
  • Exclusion Criteria:
  • Excess lower facial fat, jowling, loose or lax skin in lower face, or parotid gland prominence that could interfere with MMPS or MMPS-P grading.
  • Asymmetry of left and right sides of the face that could prevent identical MMPS or MMPS-P grading on both sides of the face.
  • History of or current temporomandibular disorder (TMJD), or presence of signs/symptoms of possible TMJD.

About Abbvie

AbbVie is a global biopharmaceutical company dedicated to developing innovative therapies that address complex health challenges. Founded in 2013 as a spin-off from Abbott Laboratories, AbbVie focuses on key therapeutic areas, including immunology, oncology, neuroscience, and virology. The company is committed to advancing scientific research and delivering groundbreaking treatments that enhance patient outcomes and quality of life. With a robust pipeline and a strong emphasis on collaboration, AbbVie strives to transform the future of medicine through its commitment to clinical excellence and patient-centered approaches.

Locations

New Orleans, Louisiana, United States

Clarkston, Michigan, United States

Santa Monica, California, United States

Westport, Connecticut, United States

Metairie, Louisiana, United States

Wilmington, North Carolina, United States

Dublin, Ohio, United States

Nashville, Tennessee, United States

Pflugerville, Texas, United States

Bradenton, Florida, United States

San Diego, California, United States

Arlington, Virginia, United States

Los Angeles, California, United States

Dallas, Texas, United States

Pflugerville, Texas, United States

Birmingham, Alabama, United States

Metairie, Louisiana, United States

Hackensack, New Jersey, United States

Latham, New York, United States

Bellaire, Texas, United States

Phoenix, Arizona, United States

Miami, Florida, United States

Patients applied

0 patients applied

Trial Officials

ABBVIE INC.

Study Director

AbbVie

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported